Xellia rolls out vancomycin
Xellia Pharmaceuticals, a manufacturer of specialty anti-infective treatments, is launching vancomycin hydrochloride for injection.
Vancomycin injection is used to treat infections in many different parts of the body.
“As a leading global supplier of vancomycin API, we are excited to now offer vancomycin 1 g and 10 g in the United States from our vertically integrated supply chain and significant injectable manufacturing footprint,” Xellia North America president Craig Boyd said. “This is the first of many key launches that will bring Xellia’s strong portfolio of established and innovative products to patients in need of critical anti-infective treatments.”
The product had a market value of $338 million for the 12 months ending August 2018, according to IQVIA.
Vancomycin injection is used to treat infections in many different parts of the body.
“As a leading global supplier of vancomycin API, we are excited to now offer vancomycin 1 g and 10 g in the United States from our vertically integrated supply chain and significant injectable manufacturing footprint,” Xellia North America president Craig Boyd said. “This is the first of many key launches that will bring Xellia’s strong portfolio of established and innovative products to patients in need of critical anti-infective treatments.”
The product had a market value of $338 million for the 12 months ending August 2018, according to IQVIA.